Status:
ACTIVE_NOT_RECRUITING
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Advanced Breast Cancer
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)...
Detailed Description
This is a Phase II open-label, 2-Part, multi-center study in Japan. The study will be conducted in two parts: Part 1 (Cohort 1) includes participants regardless of prior CDK4/6 inhibitor use and is de...
Eligibility Criteria
Inclusion
- Japanese man or postmenopausal woman
- Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory.
- Participant has identified PIK3CA mutation (as determined by a Novartis designated laboratory)
- Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory
- Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH or SISH) test is required by local laboratory testing
- Participant has measurable disease, i.e., at least one measurable lesion as per RECIST 1.1
- Participant has advanced breast cancer
- Participant has ECOG performance status 0 or 1
Exclusion
- Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment
- Participant has received prior treatment;
- with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor for Cohort 1 and 3
- with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, AKT inhibitor or CDK 4/6 inhibitor for Cohort 2
- Participant has a known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant
- Participant with inflammatory breast cancer at screening
- Participant is concurrently using other anti-cancer therapy
- Participant has had surgery within 14 days prior to starting study drug or has not recovered from major side effects
- Participant with an established diagnosis at screening of diabetes mellitus type I or not controlled type II (based on FPG and HbA1c)
- Participant has currently documented pneumonitis /interstitial lung disease
- History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis
- Participant with unresolved osteonecrosis of the jaw
- Participant has a history of severe cutaneous reactions
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04524000
Start Date
January 8 2021
End Date
July 31 2026
Last Update
September 22 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Nagoya, Aichi-ken, Japan, 464 8681
2
Novartis Investigative Site
Nagoya, Aichi-ken, Japan, 466 8560
3
Novartis Investigative Site
Nagoya, Aichi-ken, Japan, 467-8602
4
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277 8577